Literature DB >> 10412701

[Visual field defects due to antiepileptic drugs].

H Stefan1, J Bernatik, J Knorr.   

Abstract

Within the last years several reports concerning visual field defects, associated with antiepileptic drugs, have been published. In addition to antiepileptic drugs several other causes (e.g. retinopathy or chloroquine, phenothiazine etc.) may induce visual field disturbances. Visual field defects have been observed during vigabatrine, tiagabine, gabapentine, diazepam, phenytoine, and carbamazepine treatment. In 13 to 46% visual field defects are reported to be linked with epilepsies. In addition to general population based studies concerning visual field defects and prospective etiological studies in epilepsies, preclinical studies for the examination of the pathomechanism of visual field defects are necessary.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10412701     DOI: 10.1007/s001150050479

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  6 in total

1.  A controlled study comparing visual function in patients treated with vigabatrin and tiagabine.

Authors:  G L Krauss; M A Johnson; S Sheth; N R Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-03       Impact factor: 10.154

2.  Evaluation of Ocular Side Effects in the Patients on Topiramate Therapy for Control of Migrainous Headache.

Authors:  Omid Hesami; Seyedeh Simindokht Hosseini; Nasim Kazemi; Seyed-Mostafa Hosseini-Zijoud; Nahid Beladi Moghaddam; Farhad Assarzadegan; Sara Mokhtari; Shahrzad Fakhraee
Journal:  J Clin Diagn Res       Date:  2016-03-01

3.  Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study.

Authors:  John M Wild; Catherine Chiron; Hyosook Ahn; Michel Baulac; Joseph Bursztyn; Enrico Gandolfo; Ivan Goldberg; Francisco Javier Goñi; Florence Mercier; Jean-Philippe Nordmann; Avinoam B Safran; Ulrich Schiefer; Emilio Perucca
Journal:  CNS Drugs       Date:  2009-11       Impact factor: 5.749

Review 4.  Visual field defects with vigabatrin: epidemiology and therapeutic implications.

Authors:  R Kälviäinen; I Nousiainen
Journal:  CNS Drugs       Date:  2001       Impact factor: 6.497

5.  Ocular adverse effects of Topiramate: Two case reports.

Authors:  Ananya Mandal; Suparna Chatterjee; Sagarmay Bose; Gautam Ganguly
Journal:  Indian J Pharmacol       Date:  2008-11       Impact factor: 1.200

Review 6.  Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics, SSRIs and NSAIDs.

Authors:  Lise Aagaard; Ebba Holme Hansen
Journal:  BMC Clin Pharmacol       Date:  2009-03-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.